A homogeneous high-DAR antibody–drug conjugate platform combining THIOMAB antibodies and XTEN polypeptides
Neelie T. Zacharias, Vladimir N. Podust, Kimberly K. Kajihara, Douglas D. Leipold, Geoffrey Del Rosario, Desiree A. Thayer, Emily Dong, Maciej Paluch, David Fischer, Kai Zheng, Corinna Lei, Jintang He, Carl Ng, Dian Su, Luna Liu, Shabkhaiz Masih, William S. Sawyer, Jeff N. Tinianow, Jan Mařı́k, Victor Yip, Guangmin Li, Josefa Chuh, J. Hiroshi Morisaki, Summer Park, Bing Zheng, Hilda Hernández-Barry, Kelly M. Loyet, Min Xu, Katherine R. Kozak, Gail D. Lewis Phillips, Ben‐Quan Shen, Cong Wu, Keyang Xu, Shang‐Fan Yu, Amrita V. Kamath, Rebecca K. Rowntree, Dorothea Reilly, Thomas H. Pillow, Andrew G. Polson, Volker Schellenberger, Wouter L. W. Hazenbos, Jack Sadowsky
Abstract
Efficiency of targeted cell delivery of small molecules was enhanced in cells and animals via a novel well-defined bioconjugation platform combining site-specific antibody conjugation and XTEN polypeptides to enable high payload loading.